Joohyuk Sohn
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Lung Cancer Research Studies
Most-Cited Works
- → Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer(2022)2,396 cited
- → Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer(2019)1,885 cited
- → MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer(2017)1,679 cited
- → MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy(2017)1,620 cited
- → Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial(2012)1,303 cited
- → Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial(2020)1,030 cited
- → Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer(2019)1,001 cited
- → Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial(2018)986 cited
- → The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2(2019)960 cited
- → Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer(2010)883 cited